DOV Pharmaceutical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- 13
- Market Cap
- -
- Website
- http://www.dovpharm.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:1
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (75.0%)Phase 2
1 (25.0%)Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: DOV 21, 947Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- DOV Pharmaceutical, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00659347
- Locations
- 🇺🇸
Comprehensive Psychiatric Care, Norwich, Connecticut, United States
🇺🇸Future Care Studies, Springfield, Massachusetts, United States
🇺🇸Center for Emotional Fitness, Cherry Hill, New Jersey, United States
Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain
Phase 3
Completed
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2006-06-23
- Lead Sponsor
- DOV Pharmaceutical, Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT00295711
Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain
Phase 3
Completed
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2007-01-30
- Lead Sponsor
- DOV Pharmaceutical, Inc.
- Registration Number
- NCT00295724
Long-Term Safety Study of Bicifadine for the Treatment of Chronic Low Back Pain
Phase 3
Completed
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2007-03-27
- Lead Sponsor
- DOV Pharmaceutical, Inc.
- Target Recruit Count
- 1250
- Registration Number
- NCT00281645
News
No news found